Last reviewed · How we verify
Braintree Laboratories — Portfolio Competitive Intelligence Brief
4 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| PEG3350 | PEG3350 | marketed | Other | |||
| FDA approved bowel preparation containing electrolytes | FDA approved bowel preparation containing electrolytes | marketed | ||||
| HalfLytely with Bisacodyl Tablets Bowel Prep Kit | HalfLytely with Bisacodyl Tablets Bowel Prep Kit | marketed | ||||
| SUPREP Bowel Prep Kit | SUPREP Bowel Prep Kit | marketed | Osmotic laxative | Intestinal lumen | Metabolic | |
| Magnesium bowel preparation | Magnesium bowel preparation | phase 3 | ||||
| Visicol | Visicol | phase 3 | Other |
Therapeutic area mix
- Other · 2
- Metabolic · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ahmed M Maged, MD · 1 shared drug class
- Amsterdam UMC, location VUmc · 1 shared drug class
- Azienda Policlinico Umberto I · 1 shared drug class
- Bayer · 1 shared drug class
- Benaroya Research Institute · 1 shared drug class
- Bo-In Lee · 1 shared drug class
- Brooke Army Medical Center · 1 shared drug class
- Aboca Spa Societa' Agricola · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Braintree Laboratories:
- Braintree Laboratories pipeline updates — RSS
- Braintree Laboratories pipeline updates — Atom
- Braintree Laboratories pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Braintree Laboratories — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/braintree-laboratories. Accessed 2026-05-16.